Member for

2 years 1 month
Sobi has the right to participate in 50 per cent of the future earnings in the U.S

Member for

2 years 7 months

Member for

2 years 7 months

Macrophage Activation Syndrome(MAS)/ Secondary Hemophagocytic Lymphohistiocytosis (HLH) in children with Systemic Juvenile Idiopathic Arthritis

Read more about the clincal trial on http://clinicaltrials.gov

Member for

2 years 7 months

BIVV002/EXTEN-B

More about clinical trials here: http://clinicaltrials.gov
 
A Bioverativ development programme. Sobi has elected to add the programme to the collaboration agreement with Bioverativ but has not yet opted-in.

Member for

2 years 7 months

A Non controlled,  Open-Label, Multicenter, Exploratory Phase 2 Study of Efficacy of rFVIIIFC for ITI in severe hemophilia A patients with inhibitors who have failed  previous ITI  therapies

ClinicalTrials.gov Identifier: NCT03103542